BOCA RATON, Fla., Nov. 3, 2016 /PRNewswire/ -- The first annual "CNS Summit Pharma Innovation Index", launched at CNS Summit 2016, ranked life science companies developing new treatments, based on publicly available information, with regards to three facets of innovation: Trial Optimization, Digital Advancement, and Innovative Partnerships.
Photo - http://photos.prnewswire.com/prnh/20161102/435626-INFO
Logo - http://photos.prnewswire.com/prnh/20161102/435625LOGO
A fundamental driver of growth and advancement, innovation is one of the principal values of the CNS Summit, where participants from technology, pharma, biotech, investigative sites, and service companies meet to shape the future. Through cutting-edge keynote presentations from leaders transforming the clinical development industry, to innovative demonstrations, activities, and initiatives, the CNS Summit community actively works to overcome barriers and advance clinical development through collaboration, innovation and technology.
The goal of the Innovation Index is to objectively assess the investments being made in innovation, encourage innovation, and allow companies to benchmark their innovation activities via an objective external source.
The CNS Summit 2016 took place October 27th – 30th, 2016 in Boca Raton, Florida. For more information, visit www.cnssummit.org.
Media Contact:
Erica Moore
858-324-1823
SOURCE CNS Summit
